pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Biosimilar · news · pharmadog
← back to Biosimilar
News · Biosimilar
37
stories
3d
How to Choose a Biologics CDMO: 4 Criteria That Matter the Most
fiercebiotech
4d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
4d
Sanofi, Regeneron broaden alliance to find their next Dupixent
biopharma dive
4d
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
6d
After GLP-1s, biosimilars are the new frontier in direct-to-employer plans
endpoints
8d
Convergence: CBER expert offers tips for effective BLA submissions
raps
8d
BsUFA commitment letter outlines changes to FDA’s biosimilar review program
raps
11d
China’s Henlius carves out $440M T-cell engager deal with Amberstone
fiercebiotech
21d
AAM sounds alarm on ‘unsustainable, race to the bottom’ for generics and biosimilars
biospace
24d
New report may spell trouble for future cheaper biologics
endpoints
26d
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
biospace
26d
Beyond China: Five other overseas destinations for biopharma dollars
biospace
27d
Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia
endpoints
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Aug 25, 26
New Jazz cancer drug approval could drive blockbuster sales
biopharma dive
Aug 20, 26
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
Aug 20, 26
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
Aug 20, 26
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
Aug 18, 26
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
Aug 18, 26
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
Aug 17, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
stat
Aug 5, 26
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
Aug 3, 26
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
biospace
Jul 31, 26
FDA drafts guidance on container closure systems, device constituents for biosimilars
raps
Jul 30, 26
Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drug
raps
Jul 30, 26
Euro Roundup: EFPIA pushes for shorter trial approval times in EU Biotech Act
raps
Jul 30, 26
FDA updates product-specific guidelines for injectable peptides
raps
Jul 30, 26
Researchers concerned by underutilization of accelerated approval in oncology
raps
Jul 30, 26
FDA unveils FY 2027 user fee rates
raps
Jul 23, 26
Euro Roundup: EMA seeks feedback on planned changes to guidance on biosimilar efficacy studies
raps
← prev
page 1 of 2
next →
